The DOI matches its Crossref record; 22 of the 22 references it cites were found in a registry or an index.
Randomized Trial of an Inhibitor of Formation of Advanced Glycation End Products in Diabetic Nephropathy
Abstract
Background/Aims: Pimagedine inhibits the formation of advanced glycation end products and slows the progression of diabetic complications in experimental models. This study was undertaken to determine if pimagedine ameliorates nephropathy in type 1 (insulin-dependent) diabetes mellitus. Methods: This was a randomized, double-masked, placebo-controlled study performed in 690 patients with type 1 diabetes mellitus, nephropathy, and retinopathy. The patients received twice daily dosing with placebo, pimagedine 150 mg, or pimagedine 300 mg for 2–4 years. The primary end point was the time to doubling of serum creatinine; the secondary end points included evaluations of proteinuria, kidney function, and retinopathy. Results: Serum creatinine doubled in 26% (61/236) of the placebo-treated patients and in 20% (91/454) of those who received pimagedine (p = 0.099). The estimated glomerular filtration rate decreased more slowly in the pimagedine-treated patients with a 36-month decrease from baseline of 6.26 ml/min/1.73 m 2 as compared with 9.80 ml/min/1.73 m 2 in the placebo-treated patients (p = 0.05), and pimagedine reduced the 24-hour total urinary proteinuria. (The mean reduction from baseline at month 36 was 732 mg/24 h at the low dose and 329 mg/24 h at the high dose as compared with 35 mg/24 h in the placebo group; p ≤ 0.001.) Fewer pimagedine-treated patients with baseline and end point evaluations (31/324; 10%) as compared with those receiving placebo (16%; 28/179) experienced a three-step or greater progression of the retinopathy (Early Treatment of Diabetic Retinopathy Study) score (p = 0.030). Three patients receiving high-dose pimagedine but none receiving low-dose treatment developed glomerulonephritis. Conclusions: While this study did not demonstrate a statistically significant beneficial effect of pimagedine on the progression of overt nephropathy resulting from type 1 diabetes, it is noteworthy in providing the first clinical proof of the concept that inhibiting advanced glycation end product formation can result in a clinically important attenuation of the serious complications of type 1 diabetes mellitus.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
(1993) · New England Journal of Medicine · doi:10.1056/nejm199309303291401 · Cited by 24,667
Prediction of Creatinine Clearance from Serum Creatinine
Cockcroft, D. W., & Gault, H. (1976) · Nephron · doi:10.1159/000180580 · Cited by 15,309
Lewis, E. J., Hunsicker, L. G., Clarke, W. R., Berl, T., Pohl, M. A., Lewis, J. B., Ritz, E., Atkins, R. C., Rohde, R., & Raz, I. (2001) · New England Journal of Medicine · doi:10.1056/nejmoa011303 · Cited by 5,987
The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy
Lewis, E. J., Hunsicker, L. G., Bain, R. P., & Rohde, R. D. (1993) · New England Journal of Medicine · doi:10.1056/nejm199311113292004 · Cited by 5,394
Doqi, K. (2002) · American Journal of Kidney Diseases · Cited by 1,285
Agodoa, L. Y. (2001) · JAMA · doi:10.1001/jama.285.21.2719 · Cited by 944
Keane, W. F., & Eknoyan, G. (1999) · American Journal of Kidney Diseases · doi:10.1016/s0272-6386(99)70442-7 · Cited by 591
Tobacco smoke is a source of toxic reactive glycation products
Cerami, C., Founds, H., Nicholl, I., Mitsuhashi, T., Giordano, D., Vanpatten, S., Lee, A., Al-Abed, Y., Vlassara, H., Bucala, R., et al. (1997) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.94.25.13915 · Cited by 549
Advanced glycation end products induce glomerular sclerosis and albuminuria in normal rats.
Vlassara, H., Striker, L. J., Teichberg, S., Fuh, H., Li, Y. M., & Steffes, M. (1994) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.91.24.11704 · Cited by 462
Horie, K., Miyata, T., Maeda, K., Miyata, S., Sugiyama, S., Sakai, H., van Ypersole de Strihou, C., Monnier, V. M., Witztum, J. L., & Kurokawa, K. (1997) · Journal of Clinical Investigation · doi:10.1172/jci119853 · Cited by 433
Beisswenger, P. J., Makita, Z., Curphey, T. J., Moore, L. L., Jean, S., Brinck-Johnsen, T., Bucala, R., & Vlassara, H. (1995) · Diabetes · doi:10.2337/diab.44.7.824 · Cited by 253
Advanced glycosylation end products in diabetic renal and vascular disease
Bucala, R., & Vlassara, H. (1995) · American Journal of Kidney Diseases · doi:10.1016/0272-6386(95)90051-9 · Cited by 211
Li, Y. M., Steffes, M., Donnelly, T., Liu, C., Fuh, H., Basgen, J., Bucala, R., & Vlassara, H. (1996) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.93.9.3902 · Cited by 179
The pathological implications of protein glycation.
Brownlee, M. (1995) · PubMed · Cited by 153
Ultrastructure of nonenzymatically glycated mesangial matrix in diabetic nephropathy
Makino, H., Shikata, K., Hironaka, K., Kushiro, M., Yamasaki, Y., Sugimoto, H., Ota, Z., Araki, N., & Horiuchi, S. (1995) · Kidney International · doi:10.1038/ki.1995.322 · Cited by 148
Berg, T. J., Bangstad, H. ‐., Torjesen, P. A., Østerby, R., Bucala, R., & Hanssen, K. F. (1997) · Metabolism · doi:10.1016/s0026-0495(97)90010-x · Cited by 124
Protein glycation in the kidney: Role in diabetes and aging
Vlassara, H. (1996) · Kidney International · doi:10.1038/ki.1996.270 · Cited by 102
Berg, T. J., Clausen, J. T., Torjesen, P. A., Dahl‐Jørgensen, K., Bangstad, H. ‐., & Hanssen, K. F. (1998) · Diabetes Care · doi:10.2337/diacare.21.11.1997 · Cited by 90
Chronic renal insufficiency: Current understandings and their implications
Bolton, W. K., & Kliger, A. S. (2000) · American Journal of Kidney Diseases · doi:10.1053/ajkd.2000.19926 · Cited by 31
Self-citationRoles of advanced glycation end-products in the progression of diabetic nephropathy
Makino, H., Shikata, K., Kushiro, M., Hironaka, K., Yamasaki, Y., Sugimoto, H., Ota, Z., Araki, N., & Horiuchi, S. (1996) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/11.supp5.76 · Cited by 26
Aminoguanidine prolongs survival in azotemic-induced diabetic rats
Friedman, E. A., Distant, D. A., Fleishhacker, J. F., Boyd, T. A., & Cartwright, K. J. (1997) · American Journal of Kidney Diseases · doi:10.1016/s0272-6386(97)90060-3 · Cited by 15
Self-citation
Cited by
Cheung, N., Mitchell, P., & Wong, T. Y. (2010) · The Lancet · doi:10.1016/s0140-6736(09)62124-3 · Cited by 3,288
Advanced Glycation End Products: Sparking the Development of Diabetic Vascular Injury
Goldin, A., Beckman, J. A., Schmidt, A. M., & Creager, M. A. (2006) · Circulation · doi:10.1161/circulationaha.106.621854 · Cited by 2,261
Mechanisms, Pathophysiology, and Therapy of Arterial Stiffness
Zieman, S. J., Melenovsky, V., & Kass, D. A. (2005) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/01.atv.0000160548.78317.29 · Cited by 1,854
Diabetic nephropathy: diagnosis, prevention, and treatment
Gross, J. L., de Azevedo, M. J., Silveiro, S. P., Canani, L. H., Caramori, M. L., & Zelmanovitz, T. (2005) · Diabetes Care · doi:10.2337/diacare.28.1.164 · Cited by 1,839
Epidemiology of diabetic retinopathy, diabetic macular edema and related vision loss
Lee, R., Wong, T. Y., & Sabanayagam, C. (2015) · Eye and Vision · doi:10.1186/s40662-015-0026-2 · Cited by 1,569
Metadata
- Authors
- Bolton, W. K., Cattran, D. C., Williams, M. E., Adler, S. G., Appel, G. B., Cartwright, K., Foiles, P. G., Freedman, B. I., Raskin, P., Ratner, R. E., Spinowitz, B. S., Whittier, F. C., Wuerth, J.-P., & for the ACTION I Investigator Group (Appendix), F.
- Venue
- American Journal of Nephrology
- Publisher
- S. Karger AG
- Published
- 2004
- Volume
- 24
- Issue
- 1
- Pages
- 32-40
- ISSN
- 0250-8095 (ISSN-L)
- 1421-9670
- OpenAlex
- W2019226618
- Cited by
- 461
- References
- 22
- FWCI
- 14.97
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.